Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2002 Jun 01;1364:510-9. doi: 10.1038/sj.bjp.0704747.
Show Gene links
Show Anatomy links
Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors.
Acuña-Castillo C
,
Villalobos C
,
Moya PR
,
Sáez P
,
Cassels BK
,
Huidobro-Toro JP
.
???displayArticle.abstract???
The pharmacological profile of a series of (+/-)-2,5-dimethoxy-4-(X)-phenylisopropylamines (X=I, Br, NO(2), CH(3), or H) and corresponding phenylethylamines, was determined in Xenopus laevis oocytes injected with cRNA coding for rat 5-HT(2A) or 5-HT(2C) receptors. The efficacy and relative potency of these drugs were determined and compared to classical 5-HT(2) receptor agonists and antagonists. The rank order of agonist potency at the 5-HT(2A) receptor was: alpha-methyl-5-HT=5-HT>m-CPP>MK-212; at the 5-HT(2C) receptor the order was: 5-HT>alpha-methyl-5-HT>MK-212>m-CPP. All these compounds were full agonists at the 5-HT(2C) receptor, but alpha-methyl-5-HT and m-CPP showed lower efficacy at the 5-HT(2A) receptor. 4-(4-Fluorobenzoyl)-1-(4-phenylbutyl)piperidine (4F 4PP) was 200 times more potent as a 5-HT(2A) antagonist than at 5-HT(2C) receptors. Conversely, RS 102221 was 100 times more potent as a 5-HT(2C) antagonist, confirming their relative receptor selectivities. The phenylisopropylamines were partial agonists at the 5-HT(2A) receptor, with I(max) relative to 5-HT in the 22+/-7 to 58+/-15% range; the corresponding phenylethylamines had lower or undetectable efficacies. All these drugs had higher efficacies at 5-HT(2C) receptors; DOI was a full 5-HT(2C) agonist. 2C-I and the other phenylethylamines examined showed relative efficacies at the 5-HT(2C) receptor ranging from 44+/-10% to 76+/-16%. 2C-N was a 5-HT(2) receptor antagonist; the mechanism was competitive at the 5-HT(2A), but non-competitive at the 5-HT(2C) receptor. The antagonism was time-dependent at the 5-HT(2C) receptor but independent of pre-incubation time at the 5-HT(2A) receptor subtype. The alpha-methyl group determines the efficacy of these phenylalkylamines at the 5-HT(2A) and 5-HT(2C) receptors.
ARUNLAKSHANA,
Some quantitative uses of drug antagonists.
1959, Pubmed
ARUNLAKSHANA,
Some quantitative uses of drug antagonists.
1959,
Pubmed
Acuña-Castillo,
ALEPH-2, a suspected anxiolytic and putative hallucinogenic phenylisopropylamine derivative, is a 5-HT2a and 5-HT2c receptor agonist.
2000,
Pubmed
,
Xenbase
Arvanov,
LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex.
1999,
Pubmed
Barnes,
A review of central 5-HT receptors and their function.
1999,
Pubmed
Baxter,
5-HT2 receptor subtypes: a family re-united?
1995,
Pubmed
Benloucif,
Serotonin-facilitated dopamine release in vivo: pharmacological characterization.
1993,
Pubmed
Bonhaus,
RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.
1997,
Pubmed
Borowsky,
Trace amines: identification of a family of mammalian G protein-coupled receptors.
2001,
Pubmed
Choi,
Immunohistochemical localisation of the serotonin 5-HT2B receptor in mouse gut, cardiovascular system, and brain.
1996,
Pubmed
Dascal,
Involvement of a GTP-binding protein in mediation of serotonin and acetylcholine responses in Xenopus oocytes injected with rat brain messenger RNA.
1986,
Pubmed
,
Xenbase
Egan,
Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors.
1998,
Pubmed
Fitzgerald,
High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
1999,
Pubmed
Glennon,
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.
1992,
Pubmed
Herndon,
Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding.
1992,
Pubmed
Jerman,
Pharmacological characterisation of human 5-HT2 receptor subtypes.
2001,
Pubmed
Kennett,
Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety.
1996,
Pubmed
Knowles,
Evidence for a role for central 5-HT2B as well as 5-HT2A receptors in cardiovascular regulation in anaesthetized rats.
1999,
Pubmed
Knowles,
Evidence that activation of central 5-HT(2B) receptors causes renal sympathoexcitation in anaesthetized rats.
2000,
Pubmed
Lobos,
The action of the psychoactive drug 2C-B on isolated rat thoracic aorta.
1992,
Pubmed
Martin,
Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature.
1994,
Pubmed
McKernan,
The pharmacology of the benzodiazepine site of the GABA-A receptor is dependent on the type of gamma-subunit present.
1995,
Pubmed
,
Xenbase
Mihic,
Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors.
1997,
Pubmed
,
Xenbase
Moran,
Protein kinase C modulates neurotransmitter responses in Xenopus oocytes injected with rat brain RNA.
1989,
Pubmed
,
Xenbase
Nelson,
Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
1999,
Pubmed
Newton,
Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs.
1996,
Pubmed
Nichols,
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
1994,
Pubmed
Porter,
Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.
1999,
Pubmed
Saez,
Alpha-adrenergic and 5-HT2-serotonergic effects of some beta-phenylethylamines on isolated rat thoracic aorta.
1994,
Pubmed
Seggel,
A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors.
1990,
Pubmed
Yamakura,
Anesthetics and ion channels: molecular models and sites of action.
2001,
Pubmed